Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
about
Duodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controlsOncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam.Ursodeoxycholic acid protects against intestinal barrier breakdown by promoting enterocyte migration via EGFR- and COX-2-dependent mechanisms.
P2860
Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ursodeoxycholic acid counterac ...... , randomized controlled trial.
@en
Ursodeoxycholic acid counterac ...... , randomized controlled trial.
@nl
type
label
Ursodeoxycholic acid counterac ...... , randomized controlled trial.
@en
Ursodeoxycholic acid counterac ...... , randomized controlled trial.
@nl
prefLabel
Ursodeoxycholic acid counterac ...... , randomized controlled trial.
@en
Ursodeoxycholic acid counterac ...... , randomized controlled trial.
@nl
P2093
P2860
P356
P1476
Ursodeoxycholic acid counterac ...... , randomized controlled trial.
@en
P2093
Alexandra M J Langers
Bjorn W H van Heumen
Elisabeth M H Mathus-Vliegen
Ellen Kampman
Fokko M Nagengast
Hennie M J Roelofs
Iris D Nagtegaal
Jan J Koornstra
M Elisa Vink-Börger
P2860
P2888
P356
10.1186/1750-1172-8-118
P577
2013-08-06T00:00:00Z
P5875
P6179
1012654189